^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eylea (aflibercept intravitreal)

    i
    Other names: BAY86-5321, AVE0005, AVE-0005, VEGF Trap-Eye, AVE 0005, BAY865321, BAY86 5321
    Company:
    Bayer, Regeneron
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor
    Related drugs:
    4d
    The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=38, Completed, Asan Medical Center | Unknown status --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    15d
    SAHLVE: The Sahlgrenska Anti-VEGF Study (clinicaltrials.gov)
    P2, N=402, Active, not recruiting, Vastra Gotaland Region | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> May 2027 | Trial primary completion date: Sep 2024 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Eylea (aflibercept intravitreal)
    17d
    Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration (clinicaltrials.gov)
    P=N/A, N=54, Not yet recruiting, Saglik Bilimleri Universitesi
    New trial • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    18d
    ARTEMIS: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=284, Recruiting, Adverum Biotechnologies, Inc. | Trial completion date: Mar 2030 --> Nov 2030 | Trial primary completion date: Apr 2027 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    19d
    The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema (clinicaltrials.gov)
    P=N/A, N=2500, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    22d
    A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=178, Recruiting, Boehringer Ingelheim | Trial primary completion date: Jul 2026 --> Apr 2027
    Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    23d
    ZEB1 and Uveal Melanoma Invasiveness. (PubMed, Int J Mol Sci)
    Effects of siRNA-dependent ZEB1 knockdown on UM cell proliferation and their sensitivity to the VEGF-A inhibitor Eylea (aflibercept) were tested by MTT and in a real-time proliferation assay...In addition, there is probably a ZEB1 feedback loop that is sensitive to a drop in VEGF-A concentration. The data obtained allow us to consider ZEB1 silencing as an auxiliary link for a combined strategy of killing UM cells.
    Journal
    |
    KDR (Kinase insert domain receptor) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    |
    Eylea (aflibercept intravitreal)
    1m
    A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=178, Recruiting, Boehringer Ingelheim | Trial completion date: Nov 2026 --> Sep 2027
    Trial completion date
    |
    Eylea (aflibercept intravitreal)
    1m
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=51, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    1m
    A Comparative Study on the Efficacy of Aflibercept biosimilar versus the Aflibercept Intravitreous Injection in the Treatment of Refractory nAMD (ChiCTR2500108770)
    P=N/A, N=80, Not yet recruiting, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer
    New trial
    |
    Eylea (aflibercept intravitreal)
    1m
    Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Kyowa Kirin Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    1m
    Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Kyowa Kirin Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)